# PD-1 Inhibitors Maintenance for cHL Post-autoHCT

> **NCT06812858** · PHASE2 · RECRUITING · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 83 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Nivolumab, Pembrolizumab

## Key facts

- **NCT ID:** NCT06812858
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-02
- **Primary completion:** 2029-09
- **Final completion:** 2030-09
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06812858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06812858, "PD-1 Inhibitors Maintenance for cHL Post-autoHCT". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06812858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*